Capricor Therapeutics Management
Management criteria checks 3/4
Capricor Therapeutics' CEO is Linda Marbán, appointed in Jan 2010, has a tenure of 12.17 years. total yearly compensation is $1.54M, comprised of 14.9% salary and 85.1% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $5.26M. The average tenure of the management team and the board of directors is 4.5 years and 12.2 years respectively.
Key information
Linda Marbán
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 14.89% |
| CEO tenure | 16yrs |
| CEO ownership | 0.4% |
| Management average tenure | 4.5yrs |
| Board average tenure | 12.2yrs |
Recent management updates
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
May 16
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Recent updates
Capricor Therapeutics: Shares Soaring After DMD Study Win - Ball Now In FDA's Court
Dec 03We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Nov 05Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Sep 09Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 24Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
May 16Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
May 09
FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel
FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Mar 29Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
Mar 19Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding
Dec 12Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission
Dec 06Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Sep 18Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel
Jul 30Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$82m |
| Jun 30 2025 | n/a | n/a | -US$70m |
| Mar 31 2025 | n/a | n/a | -US$55m |
| Dec 31 2024 | US$2m | US$229k | -US$40m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$774k | US$221k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$1m | US$210k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$2m | US$200k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$18m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$150k | -US$14m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$229k | US$157k | -US$8m |
Compensation vs Market: Linda's total compensation ($USD1.54M) is below average for companies of similar size in the US market ($USD5.37M).
Compensation vs Earnings: Linda's compensation has increased whilst the company is unprofitable.
CEO
Linda Marbán (62 yo)
Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 14yrs | US$982.40k | 0.34% $ 4.4m | |
| Co-Founder | 16yrs | US$1.54m | 0.41% $ 5.3m | |
| CFO & Corporate Treasurer | 8yrs | US$930.23k | 0.016% $ 204.0k | |
| Executive VP | 13.8yrs | US$869.56k | 0.054% $ 695.8k | |
| Chief Operating & Science Officer | less than a year | no data | no data | |
| Senior Vice President of Quality Control | 1yr | no data | no data | |
| Chief Development Officer | 1yr | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data | |
| Director of Biostatistics of Capricor Therapeutics | no data | no data | no data | |
| Consultant | no data | no data | no data |
Experienced Management: CAPR's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 14yrs | US$982.40k | 0.34% $ 4.4m | |
| Co-Founder | 12.2yrs | US$1.54m | 0.41% $ 5.3m | |
| Independent Director | 12.2yrs | US$222.23k | 0.028% $ 354.9k | |
| Independent Director | 12.2yrs | US$248.50k | 0.17% $ 2.2m | |
| Independent Director | 4.5yrs | US$203.48k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 8yrs | no data | no data |
Experienced Board: CAPR's board of directors are seasoned and experienced ( 12.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 16:39 |
| End of Day Share Price | 2026/01/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Capricor Therapeutics, Inc. is covered by 10 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |